DataMeds AI reports 14% revenue growth in Q2

DataMeds AI said second-quarter revenue rose 14% year over year to $1.779 million, topping management expectations, while the company posted a wider loss as it advanced plans for a consumer app, a medical food launch and a pending transaction involving Datavault AI and Tollo Health.

Why it matters: - DataMeds AI is trying to turn a pharmacy and health-data platform into a broader consumer health business. - The second-quarter revenue gain shows some operating momentum as the company pushes into telemedicine, app-based care, diagnostics and health data monetization. - The company also faces a deeper loss and a capital-structure reset, which makes execution on its planned launches more important.

What happened: - DataMeds AI reported second-quarter 2026 revenue of $1.779 million, up 14% sequentially from the first quarter and above management projections. - The company reported a net operating loss of $18.363 million for the quarter ended June 30, 2026, compared with a net operating loss of $6.672 million in the same quarter a year earlier. - Net loss per share was $7.13 on 2.574 million weighted average shares outstanding, versus a loss of $5.50 per share on 1.235 million weighted average shares a year earlier. - DataMeds AI said it expects to launch the Health Lives Here consumer app with National Football League Alumni Health in September 2026. - The planned app is aimed at patients on or considering GLP-1 agonist medications in rural communities through local independent pharmacies.

The details: - The company said it recently made companion medical food Forzet available through its pharmacy-focused Corexa Health division. - Forzet is indicated for the dietary management of muscle associated with weight-loss therapies. - DataMeds AI entered an agreement to expand its Datavault AI PharmacyChain license to commercial healthcare. - The same agreement includes plans to acquire QOLPOM patent portfolios related to biometric confirmation of drug consumption through wearables and biometric confirmation of drug delivery recipients via drones. - DataMeds AI also plans to acquire a controlling interest in Tollo Health as part of the Datavault Transaction. - The company raised $6.5 million in new funding during the quarter. - DataMeds AI restructured $14.5 million in pre-existing debt and said the restructuring provides a path to a preferred equity swap. - The company completed a 1-for-50 reverse stock split. - DataMeds AI entered lock-up agreements with holders of 1,533,930 common shares. - The company formed a joint venture with KareRx that provides access to additional hub services, including electronic benefits verification, Corexa Pharmacy, Health Lives Here and access to 200,000 patient lives. - In the third quarter to date, DataMeds AI changed its corporate name and stock symbol to DataMeds AI, Inc. and MEDS. - The company appointed Brett Thompson as chief technology officer. - DataMeds AI updated the Datavault Transaction terms for tax optimization. - The pharmacy-focused division was rebranded under the Corexa Health umbrella. - Corexa Pharmacy launched Tollo Health products Tollovid and Galectovid. - Gerald Commissiong appeared on Fox Business with NFL legend Emmitt Smith to discuss NFLAH support for Health Lives Here.

Between the lines: - The company is building a more integrated model that ties together consumer apps, pharmacy distribution, telemedicine, laboratory testing, wearables and blockchain-based data handling. - Management is also signaling that patient data could become a monetization engine, with opt-in profiles feeding EinsteinRx insights and eventual blockchain tokenization. - The wider loss suggests the company is still investing heavily in the infrastructure needed for that model. - The planned drone-delivery service with biometric confirmation would push DataMeds AI into a highly experimental part of healthcare logistics if it reaches launch. - DataMeds AI said Cleveland Clinic recently completed the first medical products drone service in the United States, but that service did not include biometric confirmation of the recipient.

What's next: - DataMeds AI expects to launch the Health Lives Here app in September 2026. - The company expects to launch Forzet in the second half of 2026. - Management also expects to close the Datavault Transaction later in 2026. - The company said it intends to acquire a CLIA lab, which would add direct-to-consumer testing and deepen patient data integration. - DataMeds AI also plans to launch a drone service for medical-product delivery with biometric confirmation. - More information is available in the company's announcement and at DataMeds AI.

The bottom line: - DataMeds AI posted revenue growth, but the larger story is execution: the company is spending to build a multi-part healthcare platform and needs its upcoming launches to land.